Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates.
PK/PD
Pseudomonas aeruginosa
XDR
ceftolozane/tazobactam
hollow-fiber
Journal
Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614
Informations de publication
Date de publication:
29 06 2022
29 06 2022
Historique:
pubmed:
14
6
2022
medline:
2
7
2022
entrez:
13
6
2022
Statut:
ppublish
Résumé
The aim of this study was to compare the efficacy of intermittent (1-h), extended (4-h), and continuous ceftolozane-tazobactam (C/T) infusion against three extensively drug-resistant (XDR) sequence type (ST) 175 P. aeruginosa isolates with different susceptibilities to C/T (MIC = 2 to 16 mg/L) in a 7-day hollow-fiber infection model (HFIM). C/T in continuous infusion achieved the largest reduction in total number of bacterial colonies in the overall treatment arms for both C/T-susceptible and -resistant isolates. It was also the only regimen with bactericidal activity against all three isolates. These data suggest that continuous C/T infusion should be considered a potential treatment for infections caused by XDR P. aeruginosa isolates, including nonsusceptible ones. Proper use of C/T dosing regimens may lead to better clinical management of XDR P. aeruginosa infections.
Identifiants
pubmed: 35695526
doi: 10.1128/spectrum.00892-22
pmc: PMC9241897
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cephalosporins
0
ceftolozane
37A4IES95Q
Tazobactam
SE10G96M8W
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0089222Références
Antimicrob Agents Chemother. 2011 Dec;55(12):5685-95
pubmed: 21911563
J Chromatogr Sci. 2016 Jul;54(6):1037-40
pubmed: 27048639
Drugs. 2014 Jan;74(1):31-51
pubmed: 24352909
Antimicrob Agents Chemother. 2018 Apr 26;62(5):
pubmed: 29530842
J Antimicrob Chemother. 2007 Feb;59(2):285-91
pubmed: 17135183
Infect Drug Resist. 2013 Nov 29;6:215-23
pubmed: 24348053
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7415-7423
pubmed: 27736752
Antimicrob Agents Chemother. 2014 Oct;58(10):6024-31
pubmed: 25070105
Drug Resist Updat. 2015 Jul-Aug;21-22:41-59
pubmed: 26304792
J Antimicrob Chemother. 2018 Apr 1;73(4):942-952
pubmed: 29272436
Antimicrob Agents Chemother. 2020 Mar 24;64(4):
pubmed: 32041712
Antimicrob Agents Chemother. 2017 Oct 24;61(11):
pubmed: 28874376
Antimicrob Agents Chemother. 2018 Apr 26;62(5):
pubmed: 29483119
Antimicrob Agents Chemother. 2019 Sep 23;63(10):
pubmed: 31358583
Infection. 2018 Aug;46(4):461-468
pubmed: 29594953
Expert Rev Anti Infect Ther. 2018 May;16(5):367-368
pubmed: 29727213
Clin Exp Optom. 2018 Mar;101(2):162-171
pubmed: 29044738
Clin Case Rep. 2018 May 28;6(7):1308-1312
pubmed: 29988582
Expert Rev Anti Infect Ther. 2013 Mar;11(3):297-308
pubmed: 23458769
Antimicrob Agents Chemother. 2019 Apr 25;63(5):
pubmed: 30833428
Minerva Anestesiol. 2014 Dec;80(12):1302-9
pubmed: 24762706
Eur J Clin Microbiol Infect Dis. 2019 Aug;38(8):1457-1461
pubmed: 31073653
Sci Rep. 2019 Jan 24;9(1):487
pubmed: 30679735
Eur J Clin Microbiol Infect Dis. 2018 Nov;37(11):2191-2200
pubmed: 30141088
P T. 2014 Dec;39(12):825-32
pubmed: 25516692
Infect Dis Clin North Am. 2016 Jun;30(2):441-464
pubmed: 27208767
Sci Rep. 2021 Nov 12;11(1):22178
pubmed: 34773066
J Antimicrob Chemother. 2017 Oct 1;72(10):2813-2816
pubmed: 29091209